United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $1.52, $0.26 better than the analyst estimate of $1.26. Revenue for the quarter came in at $242.5 million versus the consensus estimate of $227.63 million.

United Therapeutics reaffirmed FY2012 guidance.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

Earnings Guidance